DELRAY BEACH, Fla. & CHASKA, Minn.--(BUSINESS WIRE)--VeriChip Corporation (“VeriChip”) (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that a significant milestone has been achieved toward the development of an in vivo glucose-sensing RFID microchip. Upon successful completion of the in vivo glucose-sensing RFID development program, this self-contained, implantable bio-sensing device will, for the first time, have the ability to measure glucose levels in the human body through an external scanner, thereby eliminating the need for diabetics to prick their fingers multiple times per day.
